ClinicalTrials.gg
CompletedNCT04332978LB1108Updated Apr 8, 2020

Topical Nasal Fluticasone Propionate in the Control of Allergic Rhinitis SymptomsPerene

A Phase 3 interventional study of Fluticasone Propionate in Perennial Allergic Rhinitis, sponsored by Libbs Farmacêutica LTDA. Completed. Open to participants aged 12 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-04-08.

Sponsored by Libbs Farmacêutica LTDA · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
566
Allocation
Randomized
Ages
12 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing fluticasone in Rhinitis, Allergic, Perennial — 1 open to participants now, 1 under way, none of them phase 3. Fluticasone · Rhinitis, Allergic, Perennial.

Enrollment
2nd of 21
566 · median 288
Started
2014
the only one that year
Phase 3
12 of 21
none open now
Registered
19th of 21
by date
Lead sponsor
1 of 21
Libbs Farmacêutica LTDA

Among the 21 studies testing fluticasone in Rhinitis, Allergic, Perennial, this one is the 2nd largest by enrollment, is the only one that started in 2014, is one of 12 in phase 3, and was the 19th registered.

Rhinitis, Allergic, Perennial

178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.

Browse Rhinitis, Allergic, Perennial studies →

Open to participants now

1 of the 21 studies testing fluticasone in Rhinitis, Allergic, Perennial is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 3 Rhinitis, Allergic, Perennial studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 12 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing fluticasone in Rhinitis, Allergic, Perennial, or all of them as a file.
02

Study summary

Phase III Study to Demonstrate the non inferiority of PLURAIR® branded nasal topical Fluticasone Propionate (FP) in relation to the FLIXONASE® brand reference drug in the control of nasal symptoms related to perennial allergic rhinitis.

Read the detailed description

This study was conducted to demonstrate the non inferiority of the topical nasal fluticasone propionate of the brand Plurair® in relation to the reference drug Flixonase® in the control of symptoms related to perennial allergic rhinitis. Allergic rhinitis is one of the most common forms of non-infectious rhinitis, characterized mainly by symptoms such as sneezing, runny nose and nasal congestion. Depending on the time of exposure to allergens and the duration of symptoms, allergic rhinitis is classified as perennial (OKUBO, 2009).

Studies for the assessment of perennial allergic rhinitis through symptom analysis used diaries provided to the participants, so that they could describe their symptoms, starting in the screening phase and ending at the end of treatment. In the present study, participants recorded, in the diary, the severity of their rhinitis symptoms (obstruction, runny nose, nasal itching and sneezing) and also associated eye symptoms (watery eyes, itchy eyes and redness) using a four-point scale (0-absent, 1-mild, 2-moderate and 3-severe). For the purpose of analyzing the primary parameter, the total daily reflective nasal symptoms (NRT) was obtained by averaging the total morning and evening scores for each day ([morning NRT + night NRT] / 2) of the individual nasal symptoms - obstruction, itching, runny nose and sneezing - assessed reflexively in the last 12 hours.

This study in its design and analysis of efficacy and safety followed the guidelines of regulatory agencies in the United States of America (FDA, 2000) and Canada (CANADA HEALTH, 2011).

Fluticasone propionate is a potent intranasal corticosteroid with negligible bioavailability, effective in the treatment of nasal symptoms of allergic rhinitis. The onset of the therapeutic effect of fluticasone propionate occurs within 12 hours when 200 μg of the medication is administered once a day (RATNER, 2008).

Following guidelines for the use of fluticasone propionate and guidelines for the assessment of symptoms of perennial allergic rhinitis, the objective of the present clinical study was to evaluate the efficacy and safety of two formulations of fluticasone propionate as a single agent in the treatment of perennial allergic rhinitis through relief of nasal symptoms assessed by recording in the participants' symptom diary.

This study was conducted in accordance with the proposal for the treatment of perennial allergic rhinitis, with local clinical research regulations, with the International Harmonization Conference (ICH) Good Clinical Practices and with the principles of the Declaration Helsinki and their respective revisions.

03

Conditions studied

  • Perennial Allergic Rhinitis

Keywords

  • Plurair
  • Fluoticasone propionate
  • topic
  • nasal
04

Who can participate

Ages eligible
12 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged ≥ 12 years and \<60 years old on the date of the selection visit;
  • Clinical history suggestive of perennial allergic rhinitis for at least 02 years;
  • Atopy proved through positive evaluation for at least one inhaled allergen (valid positive RAST test performed up to 12 months before the date of the selection visit - or positive Phadiatop® ** performed during the selection period);
  • Present the score for reflective nasal symptoms (runny nose, nasal itching, nasal obstruction and sneezing) equal to or greater than the average of 12 points out of a total of 24, during the 4 days preceding the randomization visit OR Present a score of reflective nasal symptoms (runny nose, itchy nose, nasal obstruction and sneezing) at least 12, for at least 4 days, not necessarily consecutive, within a seven-day selection period;
  • "Research participant's diary - selection" correctly filled out, considering at least 80% of the completed information regarding nasal and ocular symptoms in the two periods (morning and night);
  • Availability of telephone contact for follow-up;
  • Signature of the Free and Term and Free and Informed Consent Term, when applicable.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation;
  • Women who declare that they have the potential to become pregnant and do not want to adopt any method, including: sexual abstinence, mechanical barrier, IUD, oral contraceptive, injectable contraceptive, hormonal implant, hormonal transdermal patch, prior sterilization, etc;
  • Other clinical forms of rhinitis: seasonal allergic, medication, vasomotor, atrophic, etc;
  • History compatible with IVAS or acute sinusitis in the 15 days prior to the selection visit, symptomatic chronic sinusitis, nasal polyposis;
  • Concomitant cardiovascular / hepatic / pulmonary / renal / neurological / neoplastic disease and others, which medical criteria may compromise the patient's participation in the study;
  • Current smoking or previous smoking for less than 3 months;
  • Cataract, glaucoma, herpes simplex ocular;
  • Asthma, with the exception of controlled conditions (GINA Criteria - Global Initiative for Asthma - modified: absence of daytime symptoms, nighttime despair and experiences in experimental activities) without the need for specific medication;
  • Previous use of:
  • Antihistamine for less than 10 days with the exception of azelastine / astemizole for less than 12 weeks.
  • Topical, intranasal and systemic for less than 4 weeks;
  • Antileukotriene / anticholinergic / antifungal / antibiotics less than 7 days ago
  • Intranasal or systemic decongestant for less than 03 days;
  • Non-hormonal anti-inflammatory, including acetylsalicylic acid with use in less than 10 days;
  • Use of drugs with the potential to alter cytochrome P450 (eg, ritonavir and ketoconazole, but not exclusively) or with possible clinical influence (eg, tricyclic antidepressants, but not exclusively) or with nasal administration (eg, insulin, but not exclusively);
  • History of nasosinusal surgery;
  • Results of laboratory selection tests with significant clinical changes (complete blood count, TGO / , TGP / ALT, salt, potassium, urea, creatinine, fasting glucose and serum cortisol), which a doctor may compromise the patient's participation in. study;
  • Serious illness or condition that the doctor may compromise the patient's participation in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
566 participants (actual)

Study arms

  • Experimental
    Group I

    Drug names: Fluticasone Propionate - PLURAIR® brand Pharmaceutical form: Nasal spray (50mcg / dose) Administration: Topical nasal route Posology 02 jets in each nostril 1 time a day - Single daily topical nasal dose of 200 mcg / day (2 jets / nostril = 100 mcg / nostril), preferably in the morning, upon waking up and at the same time, for 4 weeks. Manufacturer: Libbs Farmacêutica Ltda. Presentation: Deliver 1 bottle of 120 doses in original packaging

    Drug: Fluticasone Propionate

  • Active comparator
    Group II

    Fluticasone Propionate - FLIXONASE® brand Nasal spray (50mcg / dose) Topical nasal route 02 jets in each nostril once a day - Single daily topical nasal dose of 200 mcg / day (2 jets / nostril = 100 mcg / nostril), preferably in the morning, upon waking up and at the same time, for 4 weeks. GlaxoSmithKline. Deliver 1 bottle of 120 doses in original packaging

    Drug: Fluticasone Propionate

Interventions

06

What researchers measure

Primary outcomes

  1. Variation of the mean of total reflective nasal symptoms (TSNr)

    Patients should be instructed to classify and note the severity of nasal symptoms (itching, sneezing, obstruction and coryza) using the "Research participant's diary", the reflexive way in the last 12 hours, with an assessment in the morning and another at night (twice a day, regardless of specified times), with a 4-point scale below: 0: ABSENT - this symptom is not present. 1. Mild - this symptom is present, but does not bother. 2. MODERATE - this symptom is present and is substantially received, but it does not get in the way of your daily activities / sleep quality. 3. SEVERE - this symptom is present, enters substantially and gets in the way of your daily activities / sleep quality.

    Time frame: daily records over the 4 weeks of treatment in relation to their baseline value.

Secondary outcomes

  1. Variation of total instant nasal symptoms (TSNi)

    Patients should be instructed to classify and note the severity of nasal symptoms (itching, sneezing, obstruction and runny nose) individually in the "Research participant's diary", instantly in the morning (upon waking up and before using the medication, without consideration) specific times), according to the 4-point scale below: 0: ABSENT - this symptom is not present. 1. Mild - this symptom is present, but does not bother. 2. MODERATE - this symptom is present and substantially bothers, but it does not get in the way of your daily activities / sleep quality. 3. SEVERE - this symptom is present, it substantially bothers and gets in the way of your daily activities / sleep quality.

    Time frame: over the 4 weeks of treatment

  2. Variation of each nasal symptom

    Patients should be instructed to classify and note the severity of nasal symptoms (itching, sneezing, obstruction and runny nose) individually in the "Research participant's diary", in a reflexive way in the last 12 hours, with an assessment in the morning and another in the evening (twice a day, regardless of specific times), according to the 4-point scale below: 0: ABSENT - this symptom is not present. 1. Mild - this symptom is present, but does not bother. 2. MODERATE - this symptom is present and substantially bothers, but it does not get in the way of your daily activities / sleep quality. 3. SEVERE - this symptom is present, it substantially bothers and gets in the way of your daily activities / sleep quality.

    Time frame: over the 4 weeks of treatment

  3. Variation of total ocular symptoms and in each specific ocular symptom

    Patients should be instructed to classify and note the severity of eye symptoms individually - tearing, itching and redness - in the "Research participant's diary", in a reflexive way in the last 12 hours, with an assessment in the morning and another at night (two times a day, without considering specific times), according to the 4-point scale below: 0: ABSENT - this symptom is not present. 1. Mild - this symptom is present, but does not bother. 2. MODERATE - this symptom is present and substantially bothers, but it does not get in the way of your daily activities / sleep quality. 3. SEVERE - this symptom is present, it substantially bothers and gets in the way of your daily activities / sleep quality.

    Time frame: over the 4 weeks of treatment

  4. Patient's overall impression of treatment efficacy at the end of the study

    At the end of treatment (4 weeks), each patient should assess their overall satisfaction with the treatment's effectiveness, according to the following scale: 0 = complete improvement of symptoms 1. = moderate symptom improvement 2. = slight improvement of symptoms 3. = no change in symptoms 4. = slight worsening of symptoms 5. = moderate worsening of symptoms 6. = severe worsening of symptoms

    Time frame: over the 4 weeks of treatment

  5. Researcher's general impression at the end of the study

    At the end of the treatment (4 weeks), the researcher will answer about his general impression regarding the effectiveness of the treatment, according to the following scale: 0 = complete improvement of symptoms 1. = moderate symptom improvement 2. = slight improvement of symptoms 3. = no change in symptoms 4. = slight worsening of symptoms 5. = moderate worsening of symptoms 6. = severe worsening of symptoms

    Time frame: over the 4 weeks of treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Apr 2020 and a completion of Apr 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2020
First posted
Apr 3, 2020
Start
Jul 4, 2014
Primary completionActual
Apr 1, 2020
CompletionActual
Apr 1, 2020
Last update
Apr 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04332978
Lead sponsor
Libbs Farmacêutica LTDA
Responsible party
Sponsor
First posted
Apr 3, 2020
Start date
Jul 4, 2014
Primary completion
Apr 1, 2020
Completion
Apr 1, 2020
Last update
Apr 8, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion